RenovoRx (RNXT) announced that a new clinical data abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026, being held today through January 10th in San Francisco, California. The abstract, titled “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” was led by Dr. Paula Novelli of the University of Pittsburgh Medical Center. The data presented is from a sub-study of RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial, which is evaluating the use of intra-arterial gemcitabine, IAG, a drug-device combination product candidate that uses the Company’s patented Trans-Arterial Micro-Perfusion, TAMP, therapy platform, in treating locally advanced pancreatic cancer, LAPC.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance
- Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx
- RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating
- RenovoRx Earnings Call: Positive Momentum and Strategic Growth
- RenovoRx Enters Capital on Demand Sales Agreement